Thoughts from Myron — Diamonds, Prospects and MeteorsEd. note: Â Here is our second installment from longtime reader Myron Martin. As before, let us know what you think in the comments section below the article. Myron has agreed to our trading restrictions (he wonât trade the stocks he mentions for three days), but we have not reviewed, approved or screened his stocks […]
Articles
- Most Relevant
- Most Recent
We will no longer be publishing the commentary of Dr. KSS, who wrote about biotech stocks for the Irregulars for several years. Late last week, he decided to move on and resign from his work here. I imagine he will likely start his own publication of some sort in the future — all I know […]
We’ve got a strange confluence of events here, and it seems like the market is starting to draw dotted lines toward a more optimistic future… no buy or sell changes from me at the moment, just some musings about recent inflation optimism and China optimism, and how that tied in with some excitement over Berkshire’s […]
What are your thoughts on BBDA BeBevCo company? Here is what I know about them. They are the exact opposite of 5 hour energy drinks and appear to have a niche in the 5 hour liquid relaxation category. They recently were granted the rights to sell in all 78 stores in South Carolina. The big […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. Â He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]
MAKE YOUR PORTFOLIO GREAT AGAIN ! This thread is a continuation of several threads posted previously by the author on gold and silver and hard asset investments. I am still a believer in hard assets. I also believe we are entering a period of inflation with continued dollar devaluation, higher interest rates, and a sluggish […]
This tread is created for serious cannabis investors to share K.A.S.H. by providing ideas, diligence, links, equities, etc. with like-minded individuals.
[Ed. Note: Here is the latest contribution from Dr. KSS, who writes for the Irregulars about medicine and biomedical stocks. As always, he has agreed to our trading restrictions and his words and thoughts are his own.] The Belle of the Everglades How To Profit From The Cure First of Two Parts Of the many […]
This delightful ad has clearly graced many an inbox over the past few days — I know I’ve gotten it about a dozen times myself, not to mention the hundreds of Gumshoe readers who have also been kind enough to send it along. OK, dozens. Still. So the marketing push is on … … but, […]
I follow SG by subscribing to the emailed comment notifications and use them to collect KSSâ comments for maintaining the Love KSS spreadsheet (more about that later, see the current KSS thread for its URL). I go to a thread online only (usually) when I need to clarify something about a KSS statement. Since […]
Streetsifter strikes again — he sent in this solution for an email that just started circulating, and he sent it in before I had even gotten around to reading the email. He even wrote it up nicely, so most of what follows is just a minor edit of his words (I agree he’s clearly got […]
Hi folks — this is a submission from a reader that I haven’t yet looked at, so you can follow up for yourselves. Don’t want to delay it while I try to find time, so have at it: The email ad in question is for the Venture Insider, and you may have seen this one […]
Hi Doc, There is a teaser which talks about 3 hot companies working on pain relieving which can provide huge gains apparently. It mentions about an Arizona and Vancouver-based companies .. http://www.angelnexus.com/o/web/68345/ Google search for delta-9 gave the following companies which are doing phase3 clinical trials .. InMed Pharmaceuticals http://investorshub.advfn.com/InMed-Pharmaceuticals-Inc-IMLFF-28415/ http://www.marketwatch.com/story/inmed-pharma-proprietary-platform-growing-pipeline-low-valuation-2014-10-29 GW Pharma and Insys […]
Wondering if you are going to look into the advert? I am not sure of the protocol but i have been following your methods for a year or more and love to eugooglize. So i came up with my own guesses for the pitch for the Personal Finance newsletter i received today. I am a […]
Cytodyn (CYDY) is a stock that was discussed in depth here around 4 years ago. The company makes a monoclonal antibody called leronlimab (formerly known as PRO 140) which is a CCR5 inhibitor for treating HIV. The BLA has been submitted for it and the FDA has granted it fast track designation and a decision […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]
The first version of this story was published on March 4, 2021, and the ad we were covering was also a repeat of a pitch that started appearing about six months earlier. A very similar ad is online now (don’t know if it has been distributed, or if it’s just a lingering old copy), and […]
I’ve gotten a few questions in recent weeks about a new ad for Curzio Venture Opportunities ($249/month or $2,500/yr, no refunds), which is Frank Curzio’s “high end” upgrade newsletter, focusing on small cap stocks and stuff like junior miners, biotech and private placements. And this one’s a doozy, promoting the idea that a tiny company, […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: âIn which the author and readerâŚfall into a very grave and instructive discourse.â This may prove to be a more unleavened column than […]
“What most investors don’t realize is that for a limited time, one American bank is offering an exclusive, under-the-radar CD that yields up to 13.16% annually. And just like any other CD – the principal is 100% insured by the FDIC for up to $250,000.” That’s what draw my eye to the latest tease […]
“What most investors don’t realize is that for a limited time, one American bank is offering an exclusive, under-the-radar CD that yields up to 13.16% annually. And just like any other CD – the principal is 100% insured by the FDIC for up to $250,000.” That’s what draw my eye to the latest tease from […]
This is not the first time a teaser stock idea has been pitched to us as “perfect” or “almost perfect,” of course, but using such definitive terms always catches my attention. (Yet another weakness of your friendly neighborhood Gumshoe, I can’t resist the pursuit of perfection.) And as he’s done several times before, this time […]
I don’t necessarily like to gang up on the same publisher two days in a row — but, well, the great legions of Gumshoe readers are asking for it, and we do aim to please. So just like yesterday, today we’re digging through some Motley Fool foofaraw, an ad they’ve been sending out this week […]
“When this controversial law takes effect on October 1, 2011… folks who act now could get ‘hedge fund rich’” That’s how Zachary Scheidt is launching his new service, called Hedge Fund Strategist from Taipan, a publisher in the Baltimore Agora-plex (Taipan is currently in the process of renaming itself “Insiders Strategy Group,” just to keep […]
The folks at the Money Map Press are pitching one of those “kitchen sink” deals where you pay up front to get all of their newsletters for life — these are usually in the neighborhood of $3,000-5,000 with an “annual maintenance fee” that’s generally around a hundred bucks, and this one is right in line […]
I’ve spent the past couple weeks going over my updated opinions on all of the past “Idea of the Month” stocks (or at least, those that haven’t already been dropped from coverage over the years), and I promised to put them all in one big list in order of likingness (yes, I know it’s not […]
I’ve spent the past couple weeks going over my updated opinions on all of the past “Idea of the Month” stocks (or at least, those that haven’t already been dropped from coverage over the years), and I promised to put them all in one big list in order of likingness (yes, I know it’s not […]
Over the years I’ve shared a few “Idea of the Month” picks that are plays on various emerging markets — the most direct emerging and frontier market picks have been Lonrho in Africa, Brazil Fast Food in Brazil, and Nagacorp in Cambodia, so let’s check in with those. As with the rest of our annual […]
Over the years I’ve shared a few “Idea of the Month” picks that are plays on various emerging markets — the most direct emerging and frontier market picks have been Lonrho in Africa, Brazil Fast Food in Brazil, and Nagacorp in Cambodia, so let’s check in with those. As with the rest of our annual […]
Over the years I’ve shared a few “Idea of the Month” picks that are plays on various emerging markets — the most direct emerging and frontier market picks have been Lonrho in Africa, Brazil Fast Food in Brazil, and Nagacorp in Cambodia, so let’s check in with those. As with the rest of our annual […]
Over the years I’ve shared a few “Idea of the Month” picks that are plays on various emerging markets — the most direct emerging and frontier market picks have been Lonrho in Africa, Brazil Fast Food in Brazil, and Nagacorp in Cambodia, so let’s check in with those. As with the rest of our annual […]
There’s been a big push on in recent days for subscriptions to some of Doug Casey’s newsletters, with the ad that I’ve been most recently asked about being for a “combo deal” that gets you subscriptions to Casey International Speculator and their flagship Casey Report (for a “discount” price, naturally, though it renews at a […]
Marc Lichtenfeld, who we’ve covered a number of times in this space, focuses largely on biotech investments — he’s teased a number of them for a variety of different newsletters that he has helmed or contributed to, but it looks like he’s now launching a new letter from the Oxford Club called FirstLine Investor Alert. […]
Gulf Keystone Petroleum in London is the most successful wildcatter in years,see for yourself.With multi billion barrel discoveries on 4 different licenses they have become a takeover target for IOCs. http://www.gulfkeystone.com/ Check out the progress on Proactive investors http://www.proactiveinvestors.co.uk/LON:GKP/Gulf-Keystone-Petroleum-Ltd. GKP.L in London;GUKYF in USA.
Gulf Keystone Petroleum in London is the most successful wildcatter in years,see for yourself.With multi billion barrel discoveries on 4 different licenses they have become a takeover target for IOCs. http://www.gulfkeystone.com/ Check out the progress on Proactive investors http://www.proactiveinvestors.co.uk/LON:GKP/Gulf-Keystone-Petroleum-Ltd. GKP.L in London;GUKYF in USA.
This isn’t the first time we’ve seen a teaser ad that says you can “collect a $X,000 payday” — and it’s obviously appealing, there aren’t many among us who don’t find their eyes drifting toward a headline like “$6,500 payday,” even if, like your friendly neighborhood Gumshoe, you light your cigars with $100 bills. OK, […]
Roger Conrad has been a well known fan of relatively stodgy income stocks for a long time, with his Canadian Edge and Utility Forecaster both ranking among the top income-focused newsletters according to Stock Gumshoe reviewers for most of the past several years. And today’s he’s teasing us with yet another somewhat unusual income investment, […]
There’s a bit of a tendency for some newsletter publishers to use military imagery in their letters, to try to convey an image that you’re like a Navy SEAL, sneaking up on your target to dispatch a terrorist leader with maximum prejudice (or, as the case may be, buy a stock and make some money, […]
Over the last several months we’ve seen several ads touting Steve Sjuggerud’s True Wealth Systems, which is apparently a big quantitative screening “supercomputer” that Steve subcontracted to some computer programmers — and which is supposed to identify investing anomalies that he can then write about to his subscribers, who then will profit. And I can’t […]